Company Overview

Blueberries Medical Corp. is a Canada-based life sciences company operating primarily in the medical cannabis and pharmaceutical-grade cannabis derivatives industry. The company focuses on the cultivation, production, and commercialization of regulated medical cannabis products, with an emphasis on Latin American markets, particularly Colombia, where regulatory frameworks support low-cost cultivation and export-oriented pharmaceutical development. Blueberries Medical positions itself as a vertically integrated operator targeting medical, scientific, and wellness applications rather than recreational cannabis.

The company’s core revenue strategy is centered on producing pharmaceutical-grade cannabis inputs, including dried flower and cannabis-derived oils, for domestic medical use and international export. Its strategic advantage lies in Colombia’s favorable climate, low production costs, and established regulatory pathways for medical cannabis exports. Blueberries Medical was incorporated in Canada and became publicly listed through a reverse takeover transaction, subsequently shifting its operational focus to Colombia as part of its international medical cannabis strategy.

Business Operations

Blueberries Medical generates revenue through its medical cannabis cultivation, extraction, and derivative production activities, operating under Colombian licenses that permit the cultivation of psychoactive cannabis, production of extracts, and commercialization for medical and scientific purposes. Its operations are structured to support pharmaceutical-grade standards, including compliance with Good Agricultural and Collection Practices (GACP) and export-oriented quality requirements.

The company conducts its primary operations through its wholly owned Colombian subsidiary Blueberries Colombia S.A.S., which controls cultivation assets, processing facilities, and local regulatory licenses. Operations are designed to support both bulk cannabis inputs and finished or semi-finished medical products for third-party pharmaceutical and research partners. Public disclosures indicate no material joint ventures with multinational pharmaceutical firms as of the latest available filings, and data on large-scale commercial off-take agreements remains inconclusive based on available public sources.

Strategic Position & Investments

Blueberries Medical’s strategic direction emphasizes cost leadership, regulatory compliance, and export scalability within the global medical cannabis supply chain. The company has invested in cultivation infrastructure, genetics development, and extraction capabilities to support pharmaceutical-grade output rather than consumer-branded products. Its growth initiatives are focused on expanding licensed production capacity, improving yield efficiency, and accessing international medical cannabis markets where imports are permitted.

The company has pursued selective asset investments in Colombia rather than large acquisitions, prioritizing organic growth through license expansion and operational optimization. Blueberries Medical has publicly identified interest in cannabis-derived pharmaceutical inputs, active pharmaceutical ingredients (APIs), and medical research applications, though large-scale commercial validation of these initiatives remains limited. No material controlling interests in non-cannabis portfolio companies have been verified through public disclosures.

Geographic Footprint

Blueberries Medical is headquartered in Canada, with its primary operational footprint located in Colombia, which serves as the company’s cultivation, processing, and export base. Colombia represents the center of its asset base, workforce, and licensed activities, benefiting from year-round growing conditions and established medical cannabis regulations.

The company’s commercial strategy targets international medical cannabis markets, including Latin America, Europe, and other jurisdictions that permit the import of cannabis for medical or scientific purposes. While the company has indicated intent to supply multiple regions, verified recurring revenue from a broad international customer base has not been conclusively demonstrated in public filings.

Leadership & Governance

Blueberries Medical is led by a management team with experience in cannabis operations, international markets, and public company governance. The company operates under a board-led governance structure typical of Canadian-listed issuers, with oversight of regulatory compliance, capital allocation, and international expansion strategy.

Key executives include:

• Hernán Gutiérrez – Chief Executive Officer
• Juan Felipe Ardila – Chief Operating Officer
• Gabriel Pineda – Chief Financial Officer
• Pedro Viveros – Director

Management has articulated a strategic vision focused on disciplined capital deployment, pharmaceutical-grade compliance, and leveraging Colombia’s structural advantages to compete in global medical cannabis supply chains. Data on long-term executive compensation structures and incentive alignment is limited in publicly available disclosures.